14 Aug

Sartorius and Science magazine to award prize for regenerative medicine and cell therapy

Award entails publication in Science magazine and prize money of U.S. $25,000 Exceptional scientists are invited to apply Goettingen, Germany, August 14, 2017 – Sartorius, a leading international pharmaceutical and...
08 Mar

IntelliCyt Launches Novel Assay System to Accelerate Cell Line Development

The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals. Albuquerque, New...
23 Aug

NEW QSol Buffer Can Help Scientists Gain Insight From Challenging Samples

IntelliCyt is pleased to introduce the QSol buffer. Scientists need the most physiologically-relevant models to understand complex disease states. Sticky primary cells, highly concentrated samples, or large numbers of samples...
28 Jun

IntelliCyt Acquired by Sartorius

Acquisition Substantially Strengthens Premier Portfolio of Life Sciences Research Tools for Cell Analysis and Bioprocessing June 28, 2016 (Albuquerque, NM) – IntelliCyt, a leading provider of integrated platforms that accelerate...
20 Jun

Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients

Developing predictive drug sensitivity assays using cancer patient cells is one of the promises of personalized medicine. Next generation platforms must integrate immune profiling in physiologically relevant ex-vivo microenvironments to...
13 Jun

IntelliCyt Announces a New Addition to the iQue® Screener PLUS Platform During CYTO 2016

The state-of-the-art iQue Screener PLUS platform is optimized for high throughput and high content functional and phenotypic profiling of single cells in suspension. This new configuration allows researchers to benefit...
03 Jun

Massachusetts General Hospital enters into a Technology Alliance Partnership with IntelliCyt for the Development of CRISPR Functional Screening Applications

CRISPR/Cas9 genome editing technology holds great promise for identifying therapeutic drugs targets. Through high-throughput CRISPR functional screening, improving drug selection is expected to ultimately result in better, safer, more efficacious...
17 May

Frost & Sullivan Applauds IntelliCyt’s iQue® Screener Platform for Revolutionizing Drug Development and Disease Research

Use of the iQue Screener to better understand the biological mechanisms of disease early in the drug discovery process is expected to lower cost, improve lead selection and ultimately result...
10 May

AstraZeneca Enters into an Agreement with IntelliCyt for the Development of High Throughput Biology Applications

Albuquerque, NM, US and Cambridge, UK – May 10, 2016. IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody discovery and immuno-oncology research today announced a collaboration...
15 Mar

Genetic Engineering News | Feature Article – Flow Cytometry Crystal Gazing

Excerpted from editorial: “Flow cytometry may play an important role in the evolution of personalized medicine. “The future of medicine will be to personalize by understanding a patient’s unique physiology...
25 Feb

IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment

Albuquerque, New Mexico and Helsinki, Finland – February 25, 2016 IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research today announced a collaboration with the Institute...
25 Jan

IntelliCyt Corporation Announces Record 2015 Sales

Albuquerque, New Mexico – January 25, 2016 Business Wire – IntelliCyt, a leading provider of integrated platforms that accelerate drug discovery, antibody screening and immuno-oncology research, today announced record sales results for...
22 Oct

IntelliCyt Corporation Completes $7.4 Million in New Financing

Albuquerque, New Mexico – October 22, 2015 PRWeb – IntelliCyt Corporation (“IntelliCyt”), a leading provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology, announced it has completed $7.4 million...
17 Aug

SpectraGenetics joins IntelliCyt’s Technology Alliance Partner Program

Albuquerque, New Mexico – August 17, 2015 – IntelliCyt Corporation, the leading provider of innovative, high-throughput, high-content cell and bead-based screening solutions today announced its latest TAP awardee and partner,...
17 Jun

Genedata and IntelliCyt Forge Alliance to Transform Cell-based Screening in Drug Discovery

Albuquerque, New Mexico and Basel, Switzerland – June 17, 2015 – Genedata and IntelliCyt today announced an alliance that brings together the market-leading strengths of each company to transform screening...
09 May

IntelliCyt launches iQue Screener PLUS

Albuquerque, New Mexico – May 9, 2015 – IntelliCyt Corporation, a leading developer of integrated solutions that accelerate drug discovery and life science research, today announced the launch of the...
30 Dec

IntelliCyt Corporation Wins ELRIG’s Best Technology Award

Albuquerque, NM – December 30, 2014 (PRWEB) IntelliCyt Corporation was recently named winner of the Best Technology Award at European Laboratory Robotics Interest Group’s (ELRIG) 4th Annual Pharmaceutical Flow Cytometry...
23 Oct

IntelliCyt Corporation Announces Technology Access Program

Albuquerque, NM (PRWEB) October 23, 2014. IntelliCyt Corporation, a leading provider of innovative, high-throughput, high-content cell- and bead-based screening solutions today announced the completion of the first Technology Access Program (TAP)...
15 Oct

Genetic Engineering News | Feature Article – Multiplying Multiplexing’s Power

Excerpted from editorial: “It can measure primary immune cell proliferation, isolate specific subtypes by immunophenotyping, and capture a secreted cytokine profile with encoded capture beads … all in the same...

Want to learn more or request a demo?

Click Here